A Blend of Molecular Pathology, Nuclear Medicine and Clinical Pharmacology

Objective. Modern patient care depends on access to state-of-the-art diagnostics including
imaging, pathology and data analysis methods. These fields, while being in active pursuit by
several groups, cannot be regarded independently anymore. Today, a number of novel and
effective pharmaceuticals for therapeutic interventions are available but treatment response is
limited due to insufficient a priori patient selection.
If we want to expand on our understanding of disease mechanisms, shortcut target identification
and progress in the assessment of subsequent, novel therapeutic approaches, wider collaborative
efforts across existing boundaries of medical disciplines and applied sciences are needed. These
efforts must not stop at pointing to selected targets and therapies but support going the last mile
to turn effective disease management into cost-effective patient management.
This congress intends to provide a forum to open-minded experts both from academia and
industry in the field of molecular pathology, nuclear medicine, clinical pharmacology and beyond
who share this vision and like to engage in advancing effective and individualized treatments
based on novel and validated diagnostic approaches.

Further Information and Program